Tectonic Therapeutic, Inc. (TECX) stock
TECXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$21.04−0.92 (-4.19%)
Close on Nov 12, 2026Market cap $411.32MP/E –Yield 0.00%
Tectonic Therapeutic r&d expenses
Research and development expenses are spending on new products and technology.
Tectonic Therapeutic's R&D Expenses for the twelve months ending Sep 30, 2026 was $72.70M, up 29.1% year over year. For fiscal 2025 it was $63.49M, up 53.5% from the year before. The highest annual figure on record is $87.24M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $63.49M | +53.5% |
| FY2024 | Dec 31, 2024 | $41.36M | +11.9% |
| FY2023 | Dec 31, 2023 | $36.97M | -48.8% |
| FY2022 | Dec 31, 2022 | $72.19M | -13.1% |
| FY2021 | Dec 31, 2021 | $83.11M | -4.7% |
| FY2020 | Dec 31, 2020 | $87.24M | +58.7% |
| FY2019 | Dec 31, 2019 | $54.97M | +56.6% |
| FY2018 | Dec 31, 2018 | $35.10M | +131.0% |
| FY2017 | Dec 31, 2017 | $15.19M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $17.44M | +3.0% |
| Q2 FY2026 | Jun 30, 2026 | $18.05M | +5.0% |
| Q1 FY2026 | Mar 31, 2026 | $20.87M | +60.1% |
| Q4 FY2025 | Dec 31, 2025 | $16.34M | +78.5% |
| Q3 FY2025 | Sep 30, 2025 | $16.93M | +18.2% |
| Q2 FY2025 | Jun 30, 2025 | $17.19M | +142.9% |
| Q1 FY2025 | Mar 31, 2025 | $13.04M | +20.5% |
| Q4 FY2024 | Dec 31, 2024 | $9.16M | +27.3% |
| Q3 FY2024 | Sep 30, 2024 | $14.32M | +76.0% |
| Q2 FY2024 | Jun 30, 2024 | $7.07M | -19.3% |
| Q1 FY2024 | Mar 31, 2024 | $10.82M | -37.6% |
| Q4 FY2023 | Dec 31, 2023 | $7.19M | -60.3% |
| Q3 FY2023 | Sep 30, 2023 | $8.13M | -48.9% |
| Q2 FY2023 | Jun 30, 2023 | $8.77M | -53.6% |
| Q1 FY2023 | Mar 31, 2023 | $17.33M | -10.0% |
| Q4 FY2022 | Dec 31, 2022 | $18.14M | -4.5% |
| Q3 FY2022 | Sep 30, 2022 | $15.92M | -30.9% |
| Q2 FY2022 | Jun 30, 2022 | $18.88M | -16.3% |
| Q1 FY2022 | Mar 31, 2022 | $19.25M | +3.9% |
| Q4 FY2021 | Dec 31, 2021 | $19.00M | -3.0% |
| Q3 FY2021 | Sep 30, 2021 | $23.04M | -19.2% |
| Q2 FY2021 | Jun 30, 2021 | $22.54M | +8.0% |
| Q1 FY2021 | Mar 31, 2021 | $18.53M | +1.4% |
| Q4 FY2020 | Dec 31, 2020 | $19.59M | +13.8% |
| Q3 FY2020 | Sep 30, 2020 | $28.51M | +118.6% |
| Q2 FY2020 | Jun 30, 2020 | $20.87M | +70.1% |
| Q1 FY2020 | Mar 31, 2020 | $18.27M | +46.8% |
| Q4 FY2019 | Dec 31, 2019 | $17.22M | +34.4% |
| Q3 FY2019 | Sep 30, 2019 | $13.04M | +41.3% |
| Q2 FY2019 | Jun 30, 2019 | $12.27M | +65.6% |
| Q1 FY2019 | Mar 31, 2019 | $12.45M | +120.4% |
| Q4 FY2018 | Dec 31, 2018 | $12.81M | +98.1% |
| Q3 FY2018 | Sep 30, 2018 | $9.23M | +70.6% |
| Q2 FY2018 | Jun 30, 2018 | $7.41M | +293.8% |
| Q1 FY2018 | Mar 31, 2018 | $5.65M | – |
| Q4 FY2017 | Dec 31, 2017 | $6.47M | – |
| Q3 FY2017 | Sep 30, 2017 | $5.41M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.88M | – |
See a number that looks wrong?